ABT
ABBOTT LABORATORIESNYSEResearch view
Healthcare · Pharmaceutical Preparations · Large-cap · SEC EDGAR FY 2025-12-31
Price history
Chart: TradingView’s own feed · page prices: 1D EOD🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$177.1B
Enterprise Value$184.6B
Income$6.5B
Sales$44.3B
Book/sh$30.30
Cash/sh$4.89
Dividend TTM$2.40
Payout63%
Employees—
IPO—
Quick Ratio1.18
Current Ratio1.58
Debt/Eq0.30
EPS (ttm)$3.72
EPS this Y-51.3%
EPS past 3/5Y-1.6%
Sales past 3/5Y0.5%
EPS Y/Y TTM-51.3%
Sales Y/Y TTM5.7%
Shs Outstand1.74B
ROA7.5%
ROE12.4%
ROIC10.3%
Gross Margin—
Oper. Margin18.2%
Profit Margin14.7%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$43.1B
2021
$43.7B
2022
$40.1B
2023
$42.0B
2024
$44.3B
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B |
| Net Income | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Operating Cash Flow | $10.5B | $9.6B | $7.3B | $8.6B | $9.6B |
| Free Cash Flow | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
FY25 cash-flow waterfall
Capital-light: capex is $2.2B against $9.6B operating cash
COMMUNITY · $ABT0 theses
POST YOUR TAKE →Related Stocks
Click to exploreSame Industry · Pharmaceutical Preparations
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.